Vastus Lateralis Fiber Shift Is an Independent Predictor of Mortality in Chronic Obstructive Pulmonary Disease

To the Editor:

Quadriiceps weakness and atrophy is present in approximately 30% of patients with chronic obstructive pulmonary disease (COPD) in secondary care (1, 2). The quadriiceps also displays a shift in fiber type so that there are fewer type I (oxidative) fibers and more type II (glycolytic) fibers (3). Pulmonary rehabilitation only partially addresses this fiber shift (4). Muscle mass (5) and strength (6) are both associated with increased mortality, but the prognostic significance of fiber shift is unknown.

In a retrospective multicenter analysis of 392 patients from four sites (see Tables E1–E4 in the online supplement), mortality data were collated, as part of audit procedures, on outpatients with stable COPD who had undergone a vastus lateralis biopsy between 1995 and 2013. Data from these subjects have been previously published (e.g., References 2, 4, 5). Fiber proportion, reported as the percentage of type II fibers (type II fiber %), was established by immunohistochemistry. Fiber shift, evaluated as a dichotomous variable, was considered to have occurred when the proportion of type II fibers was greater than 68% (men) or greater than 65% (women) based on normal ranges established from an age-matched healthy population published by Natanek and colleagues (3). Body mass index (BMI), fat-free mass index (FFMI), dominant leg isometric quadriiceps maximum voluntary contraction (Q MVC and Q MVC/BMI), mid-thigh cross-sectional area determined by computed tomography scan (MT_CSA), residual volume normalized to total lung capacity (RV/TLC), and percent predicted value for the carbon monoxide transfer factor corrected for hemoglobin (TLCOC), when available, were included in subanalyses. Data were analyzed for the whole dataset and also after splitting the group into those with an FEV₁ less than 50% predicted and those with an FEV₁ greater than or equal to 50% predicted. Further details on the methodology and statistical analyses are presented in the online supplement. Some of the results of this study have been previously reported in abstract form (7).

Patients were followed up for a median of 1,699 days (127–6,601 d); 102 of 392 (26.7%) patients died during follow-up (Table E6). Cohort characteristics are presented in Tables 1 and 2 and Tables E1–E5. One hundred fifty-one patients had Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I/II disease and 241 had GOLD stage III/IV disease. Those who died were older and had a lower FEV₁ % predicted, and there was a greater male preponderance (Table E6A). One hundred seventy-seven (45.1%) of the patients had fiber shift. The patients who died had a higher percentage of type II fibers (69.5% [62.2, 76.3%] vs. 66.0% [54.0, 74.2%]; P = 0.002) and a higher proportion of them exhibited fiber shift (58% vs. 41%, P = 0.004). BMI, FFMI, Q MVC, MT_CSA, and TLCOC were all lower, and RV/TLC higher, in those who died (Table E6B).

In the cohort considered as a whole, both type II fiber % and the presence of fiber shift were univariate predictors of mortality, as were age and FEV₁ % predicted (Tables 1 and 2). In a multivariate analysis including fiber shift as a dichotomous variable, fiber shift was retained, as were age and FEV₁ % predicted, Table 1. When age, FEV₁ % predicted, and type II fiber % were entered into a multivariate analysis, age and FEV₁ % predicted were retained as independent predictors, but the association between fiber type and mortality just missed statistical significance (Table 2). The relationship between FEV₁ and fiber proportion is shown in Figure 1A, and survival as a function of fiber shift, adjusted for age and FEV₁, is shown in Figure 1B. Additional data regarding other lung function and muscle parameters are presented in Tables E7–E10. FEV₁ expressed in liters and TLCOC were also univariate predictors of mortality; however, RV/TLC was not. When including TLCOC in the analysis (n = 209), fiber shift, age, FEV₁ % predicted, and TLCOC were all independent predictors of mortality. In other subanalyses, BMI, FFMI, Q MVC, Q MVC/BMI, and MT_CSA were not univariate predictors of mortality.

When limiting the analysis to those with an FEV₁ greater than or equal to 50% predicted, age was the only predictor of mortality (hazard ratio [HR], 1.16; 95% CI, 1.07, 1.25; P < 0.0001; Table E11). In a multivariate analysis confined to those with an FEV₁ less than 50%, fiber shift was retained as an independent predictor (HR, 1.71; 95% CI, 1.08, 2.71; P = 0.02), as...
were age (HR, 1.06; 95% CI, 1.03, 1.09; \(P < 0.0001\)), and FEV\(_1\) % predicted (HR, 0.96; 95% CI, 0.94, 0.99; \(P = 0.002\); Table E12A). In a separate analysis confined to those with an FEV\(_1\) less than 50%, type II fiber % was not retained as an independent predictor (HR, 1.014; 95% CI, 0.996, 1.032; \(P = 0.13\)), whereas age and FEV\(_1\) % predicted were (Table E12B).

Fiber shift in the vastus lateralis of patients with COPD was associated with increased mortality, although this association was weaker when lung function and age were included in the analysis. This finding was pronounced in patients with GOLD stage III/IV disease but undetectable in those with GOLD stage I/II disease. The relationship between skeletal muscle atrophy (5) and weakness (6) with mortality has been previously noted in COPD. However, we believe the present analysis is timely because we (3) and others (8) have recently shown that the nature of skeletal muscle involvement in COPD is heterogeneous rather than uniform. No prior study has related quadriceps biopsy appearances to long-term outcome in COPD.

Given the known relationship between exercise capacity and survival (9), these data are consistent with our prior studies, which demonstrated a relationship between fiber shift (although not fiber atrophy) and impaired exercise capacity (3) and functional performance (10). Nevertheless, it remains unclear whether fiber shift causes poor exercise tolerance or is a manifestation of exercise intolerance and reduced physical activity, which are both associated with increased mortality in COPD (9, 11). Both concepts can be supported by in vivo models that demonstrate that muscle disuse results in type I to type II fiber shift (12) and that fiber shift toward a type I fiber predominance increases exercise performance (13). Due to the retrospective nature of the current analysis, exercise performance and physical activity data were not available for inclusion in this report, so a causative role for fiber shift in mortality cannot be demonstrated from this study. A prospective study would have been preferable and could also have considered other factors of relevance, including pulmonary rehabilitation over the intervening period. Despite the limitations of the current study, it is doubtful that a prospective study of comparable size and duration will ever be done.

Interest in pharmacological management of skeletal muscle dysfunction is growing (14), and addressing fiber shift may eventually become a therapeutic possibility. Further studies to address whether the reversal of fiber shift is of benefit are of value. ■

**Table 1.** Core Characteristics of the Cohort (n = 392) in Addition to Univariate and Multivariate Analyses Including Type II Fiber Proportion Dichotomized into the Occurrence of Fiber Shift

<table>
<thead>
<tr>
<th>Parameter</th>
<th>%/Mean (SD)/Median (IQR)</th>
<th>Univariate HR (95% CI)</th>
<th>(P) Value</th>
<th>Multivariate HR (95% CI)</th>
<th>(P) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr</td>
<td>65.9 (8)</td>
<td>1.045 (1.018, 1.072)</td>
<td>0.001</td>
<td>1.070 (1.040, 1.101)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Male sex, %</td>
<td>73</td>
<td>1.346 (0.805, 2.252)</td>
<td>0.257</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>FEV(_1) % predicted</td>
<td>41.6 (28.0, 61.0)</td>
<td>0.970 (0.957, 0.982)</td>
<td>&lt;0.0001</td>
<td>0.965 (0.951, 0.979)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Fiber shift present</td>
<td>45</td>
<td>2.073 (1.390, 3.091)</td>
<td>0.001</td>
<td>1.98 (1.056, 2.419)</td>
<td>0.027</td>
</tr>
</tbody>
</table>

**Table 2.** Core Characteristics of the Cohort (n = 392) in Addition to Univariate and Multivariate Analyses Including Type II Fiber Proportion as a Continuous Measure

<table>
<thead>
<tr>
<th>Parameter</th>
<th>%/Mean (SD)/Median (IQR)</th>
<th>Univariate HR (95% CI)</th>
<th>(P) Value</th>
<th>Multivariate HR (95% CI)</th>
<th>(P) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr</td>
<td>65.9 (8)</td>
<td>1.045 (1.018, 1.072)</td>
<td>0.001</td>
<td>1.070 (1.041, 1.101)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Male sex, %</td>
<td>73</td>
<td>1.346 (0.805, 2.252)</td>
<td>0.257</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>FEV(_1) % predicted</td>
<td>41.6 (28.0, 61.0)</td>
<td>0.970 (0.957, 0.982)</td>
<td>&lt;0.0001</td>
<td>0.965 (0.951, 0.979)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>% Type II fibers</td>
<td>66.6 (56.0, 75.0)</td>
<td>1.024 (1.008, 1.039)</td>
<td>0.002</td>
<td>1.014 (0.998, 1.030)</td>
<td>0.088</td>
</tr>
</tbody>
</table>

**Definition of abbreviations:** CI = confidence interval; HR = hazard ratio; IQR = interquartile range.
survival curves for those with fiber shift (n = 177) and those without fiber shift (n = 215) after adjusting for age and FEV1 % predicted as covariates.

Figure 1. (A) The relationship between type II fiber percentage and FEV1 % predicted (dashed lines demonstrate the 95% confidence interval), and (B) survival curves for those with fiber shift (n = 177) and those without fiber shift (n = 215) after adjusting for age and FEV1 % predicted as covariates.

Laura Disano, M.D.
Royal Brompton & Harefield NHS Foundation Trust
London, United Kingdom

Gerasimos Terzis, M.Sc., Ph.D.
National and Kapodistrian University of Athens
Athens, Greece

Nicholas S. Hopkinson, Ph.D.
Imperial College London
London, United Kingdom

Joaquim Gea, M.D.
CIBERES, ISC III
Barcelona, Spain

Ioannis Vogiatzis, Ph.D.
National and Kapodistrian University of Athens
Athens, Greece

François Maltais, M.D.
Université Laval
Québec, PQ, Canada

Michael I. Polkey, Ph.D.
Royal Brompton & Harefield NHS Foundation Trust
London, United Kingdom

References


Published 2014 by the American Thoracic Society

Spirometry in the Occupational Setting

To the Editor:

We read with great interest the recent American Thoracic Society (ATS) recommendations for performance of spirometry in the workplace (1). The first question addressed in the guideline, and about which a recommendation is made, concerns the importance of technologist training as a key component for obtaining good...